

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2024-2030

<https://marketpublishers.com/r/G1F27EB599D4EN.html>

Date: January 2024

Pages: 119

Price: US\$ 3,660.00 (Single User License)

ID: G1F27EB599D4EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Benign Prostatic Hyperplasia (BPH) Drugs market size was valued at US\$ 3257.1 million in 2023. With growing demand in downstream market, the Benign Prostatic Hyperplasia (BPH) Drugs is forecast to a readjusted size of US\$ 4122.5 million by 2030 with a CAGR of 3.4% during review period.

The research report highlights the growth potential of the global Benign Prostatic Hyperplasia (BPH) Drugs market. Benign Prostatic Hyperplasia (BPH) Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Benign Prostatic Hyperplasia (BPH) Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Benign Prostatic Hyperplasia (BPH) Drugs market.

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man's life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders

of the industry, and they hold key technologies and patents, with high-end customers.

Key Features:

The report on Benign Prostatic Hyperplasia (BPH) Drugs market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Benign Prostatic Hyperplasia (BPH) Drugs market. It may include historical data, market segmentation by Type (e.g., Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Benign Prostatic Hyperplasia (BPH) Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Benign Prostatic Hyperplasia (BPH) Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Benign Prostatic Hyperplasia (BPH) Drugs industry. This include advancements in Benign Prostatic Hyperplasia (BPH) Drugs technology, Benign Prostatic Hyperplasia (BPH) Drugs new entrants, Benign Prostatic Hyperplasia (BPH) Drugs new investment, and other innovations that are shaping the future of Benign Prostatic Hyperplasia (BPH) Drugs.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Benign Prostatic Hyperplasia (BPH) Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Benign Prostatic Hyperplasia (BPH) Drugs product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Benign Prostatic Hyperplasia (BPH) Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax

incentives, and other measures aimed at promoting Benign Prostatic Hyperplasia (BPH) Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Benign Prostatic Hyperplasia (BPH) Drugs market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Benign Prostatic Hyperplasia (BPH) Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Benign Prostatic Hyperplasia (BPH) Drugs market.

Market Segmentation:

Benign Prostatic Hyperplasia (BPH) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Segmentation by application

Hospitals

Drugstores

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

Key Questions Addressed in this Report

What is the 10-year outlook for the global Benign Prostatic Hyperplasia (BPH) Drugs market?

What factors are driving Benign Prostatic Hyperplasia (BPH) Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Benign Prostatic Hyperplasia (BPH) Drugs market opportunities vary by end market size?

How does Benign Prostatic Hyperplasia (BPH) Drugs break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Country/Region, 2019, 2023 & 2030

2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

- 2.2.1 Alpha-Blocker
- 2.2.2 Phosphodiesterase Type-5 Inhibitors
- 2.2.3 Others

2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

- 2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)
- 2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2019-2024)

2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

- 2.4.1 Hospitals
- 2.4.2 Drugstores
- 2.4.3 Others

2.5 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

- 2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2019-2024)

2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Application (2019-2024)

2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2019-2024)

3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY COMPANY

3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company

3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Company (2019-2024)

3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2019-2024)

3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Company (2019-2024)

3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2019-2024)

3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2019-2024)

3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company

3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Location Distribution

3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Geographic Region (2019-2024)

4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Geographic Region (2019-2024)

- 4.2 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country/Region (2019-2024)
 - 4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Country/Region (2019-2024)
 - 4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
- 4.4 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
- 4.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
- 4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth

5 AMERICAS

- 5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
 - 5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024)
 - 5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024)
- 5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
- 5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
 - 6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024)
 - 6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024)
- 6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
- 6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country

7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024)

7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024)

7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Country

8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024)

8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024)

8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

10.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

10.4 Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors

11.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer

12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY GEOGRAPHIC REGION

12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Region

12.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Region (2025-2030)

12.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type

12.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Eli Lilly

13.1.1 Eli Lilly Company Information

13.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

13.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Eli Lilly Main Business Overview

- 13.1.5 Eli Lilly Latest Developments
- 13.2 GlaxoSmithKline
 - 13.2.1 GlaxoSmithKline Company Information
 - 13.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 GlaxoSmithKline Main Business Overview
 - 13.2.5 GlaxoSmithKline Latest Developments
- 13.3 Astellas Pharma
 - 13.3.1 Astellas Pharma Company Information
 - 13.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.3.4 Astellas Pharma Main Business Overview
 - 13.3.5 Astellas Pharma Latest Developments
- 13.4 Sanofi
 - 13.4.1 Sanofi Company Information
 - 13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Sanofi Main Business Overview
 - 13.4.5 Sanofi Latest Developments
- 13.5 Pfizer
 - 13.5.1 Pfizer Company Information
 - 13.5.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Pfizer Main Business Overview
 - 13.5.5 Pfizer Latest Developments
- 13.6 Abbott
 - 13.6.1 Abbott Company Information
 - 13.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

- 13.6.4 Abbott Main Business Overview
- 13.6.5 Abbott Latest Developments
- 13.7 Allergan
 - 13.7.1 Allergan Company Information
 - 13.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Allergan Main Business Overview
 - 13.7.5 Allergan Latest Developments
- 13.8 TEVA
 - 13.8.1 TEVA Company Information
 - 13.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.8.4 TEVA Main Business Overview
 - 13.8.5 TEVA Latest Developments
- 13.9 Mylan
 - 13.9.1 Mylan Company Information
 - 13.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.9.4 Mylan Main Business Overview
 - 13.9.5 Mylan Latest Developments
- 13.10 Novartis
 - 13.10.1 Novartis Company Information
 - 13.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.10.4 Novartis Main Business Overview
 - 13.10.5 Novartis Latest Developments
- 13.11 Merck
 - 13.11.1 Merck Company Information
 - 13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
 - 13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and

Gross Margin (2019-2024)

13.11.4 Merck Main Business Overview

13.11.5 Merck Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Alpha-Blocker

Table 4. Major Players of Phosphodiesterase Type-5 Inhibitors

Table 5. Major Players of Others

Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)

Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (\$ million)

Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2024)

Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2019-2024) & (US\$/Unit)

Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)

Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024)

Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2024)

Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2019-2024) & (US\$/Unit)

Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2019-2024) & (M Units)

Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2019-2024)

Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2019-2024) (\$ Millions)

Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2019-2024)

- Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company (2019-2024) & (US\$/Unit)
- Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution and Sales Area
- Table 22. Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
- Table 23. Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- Table 24. New Products and Potential Entrants
- Table 25. Mergers & Acquisitions, Expansion
- Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Region (2019-2024) & (M Units)
- Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Geographic Region (2019-2024)
- Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Geographic Region (2019-2024) & (\$ millions)
- Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region (2019-2024)
- Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country/Region (2019-2024) & (M Units)
- Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2019-2024)
- Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country/Region (2019-2024) & (\$ millions)
- Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country/Region (2019-2024)
- Table 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)
- Table 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2024)
- Table 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (\$ Millions)
- Table 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2024)
- Table 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)
- Table 39. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)
- Table 40. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)

Table 41. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2024)

Table 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (\$ Millions)

Table 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2024)

Table 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 45. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)

Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2024)

Table 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2024)

Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 52. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)

Table 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2019-2024)

Table 54. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2019-2024)

Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 58. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Drugs

Table 59. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Drugs

Table 60. Key Industry Trends of Benign Prostatic Hyperplasia (BPH) Drugs

Table 61. Benign Prostatic Hyperplasia (BPH) Drugs Raw Material

- Table 62. Key Suppliers of Raw Materials
- Table 63. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
- Table 64. Benign Prostatic Hyperplasia (BPH) Drugs Customer List
- Table 65. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2025-2030) & (M Units)
- Table 66. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 67. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2025-2030) & (M Units)
- Table 68. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 69. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2025-2030) & (M Units)
- Table 70. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 71. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2025-2030) & (M Units)
- Table 72. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 73. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2025-2030) & (M Units)
- Table 74. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 75. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2025-2030) & (M Units)
- Table 76. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2025-2030) & (\$ Millions)
- Table 77. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2025-2030) & (M Units)
- Table 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2025-2030) & (\$ Millions)
- Table 79. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
- Table 80. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications
- Table 81. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 82. Eli Lilly Main Business
- Table 83. Eli Lilly Latest Developments

Table 84. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 85. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 86. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 87. GlaxoSmithKline Main Business

Table 88. GlaxoSmithKline Latest Developments

Table 89. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 90. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 91. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 92. Astellas Pharma Main Business

Table 93. Astellas Pharma Latest Developments

Table 94. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 95. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 96. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 97. Sanofi Main Business

Table 98. Sanofi Latest Developments

Table 99. Pfizer Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 100. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 101. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 102. Pfizer Main Business

Table 103. Pfizer Latest Developments

Table 104. Abbott Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 105. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 106. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 107. Abbott Main Business

Table 108. Abbott Latest Developments

Table 109. Allergan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 110. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 111. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 112. Allergan Main Business

Table 113. Allergan Latest Developments

Table 114. TEVA Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 115. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 116. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 117. TEVA Main Business

Table 118. TEVA Latest Developments

Table 119. Mylan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 120. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 121. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 122. Mylan Main Business

Table 123. Mylan Latest Developments

Table 124. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 125. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 126. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 127. Novartis Main Business

Table 128. Novartis Latest Developments

Table 129. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 130. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolios and Specifications

Table 131. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 132. Merck Main Business

Table 133. Merck Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs
- Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2019-2030 (M Units)
- Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of Alpha-Blocker
- Figure 10. Product Picture of Phosphodiesterase Type-5 Inhibitors
- Figure 11. Product Picture of Others
- Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2023
- Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2024)
- Figure 14. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Hospitals
- Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2019-2024) & (M Units)
- Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Drugstores
- Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2019-2024) & (M Units)
- Figure 18. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Others
- Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2019-2024) & (M Units)
- Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2023)
- Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2023
- Figure 22. Benign Prostatic Hyperplasia (BPH) Drugs Sales Market by Company in 2023 (M Units)
- Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company in 2023

Figure 24. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market by Company in 2023 (\$ Million)

Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2023

Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Geographic Region (2019-2024)

Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region in 2023

Figure 28. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2024 (M Units)

Figure 29. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2024 (\$ Millions)

Figure 30. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2024 (M Units)

Figure 31. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2024 (\$ Millions)

Figure 32. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2024 (M Units)

Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2024 (\$ Millions)

Figure 34. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2024 (M Units)

Figure 35. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2024 (\$ Millions)

Figure 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2023

Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2023

Figure 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)

Figure 39. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)

Figure 40. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 41. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 42. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 43. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2023

Figure 45. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2023

Figure 46. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)

Figure 47. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)

Figure 48. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 49. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 50. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 51. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 52. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 53. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 54. China Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2023

Figure 56. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2023

Figure 57. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)

Figure 58. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)

Figure 59. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 60. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 61. UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 62. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 63. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth

2019-2024 (\$ Millions)

Figure 64. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2023

Figure 65. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2023

Figure 66. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2024)

Figure 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2024)

Figure 68. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 69. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 70. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 71. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 72. GCC Country Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in 2023

Figure 74. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

Figure 75. Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs

Figure 76. Channels of Distribution

Figure 77. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Forecast by Region (2025-2030)

Figure 78. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2025-2030)

Figure 79. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2025-2030)

Figure 80. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2025-2030)

Figure 81. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2025-2030)

Figure 82. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G1F27EB599D4EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1F27EB599D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970